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Crohn	disease	(CD)	and	ulcerative	colitis	(UC)	are	increasingly	common,	chronic	forms	of	inflammatory	bowel	
disease.	The	behavior	of	these	diseases	varies	unpredictably	among	patients.	Identification	of	reliable	prognos-
tic	biomarkers	would	enable	treatment	to	be	personalized	so	that	patients	destined	to	experience	aggressive	
disease	could	receive	appropriately	potent	therapies	from	diagnosis,	while	those	who	will	experience	more	
indolent	disease	are	not	exposed	to	the	risks	and	side	effects	of	unnecessary	immunosuppression.	Using	tran-
scriptional	profiling	of	circulating	T	cells	isolated	from	patients	with	CD	and	UC,	we	identified	analogous	
CD8+	T	cell	transcriptional	signatures	that	divided	patients	into	2	otherwise	indistinguishable	subgroups.	In	
both	UC	and	CD,	patients	in	these	subgroups	subsequently	experienced	very	different	disease	courses.	A	sub-
stantially	higher	incidence	of	frequently	relapsing	disease	was	experienced	by	those	patients	in	the	subgroup	
defined	by	elevated	expression	of	genes	involved	in	antigen-dependent	T	cell	responses,	including	signaling	
initiated	by	both	IL-7	and	TCR	ligation	—	pathways	previously	associated	with	prognosis	in	unrelated	autoim-
mune	diseases.	No	equivalent	correlation	was	observed	with	CD4+	T	cell	gene	expression.	This	suggests	that	
the	course	of	otherwise	distinct	autoimmune	and	inflammatory	conditions	may	be	influenced	by	common	
pathways	and	identifies	what	we	believe	to	be	the	first	biomarker	that	can	predict	prognosis	in	both	UC	and	
CD	from	diagnosis,	a	major	step	toward	personalized	therapy.
Introduction
Crohn disease (CD) and ulcerative colitis (UC) are chronic forms 
of inflammatory bowel disease (IBD) that predominantly affect 
young adults and cause considerable morbidity. UC typically pres-
ents with bloody diarrhea, and CD typically presents with abdomi-
nal pain, weight loss, and altered bowel pattern. Although once 
considered to be “Western” diseases, principally affecting North 
America and Western Europe, it is now clear that the incidence and 
prevalence rates of these diseases are rapidly increasing in other 
parts of the world, with dramatic increases noted in India, Japan, 
China, and the Middle East (1). Accordingly, these diseases repre-
sent an increasing burden upon global health, which is likely to 
continue to increase in the future.
A major determinant of the impact of CD or UC at an individ-
ual level is the clinical course experienced by each patient, which 
is known to be highly variable (2, 3). Currently, clinicians cannot 
accurately predict at diagnosis how an individual’s disease will 
behave, and consequently, a “step-up” management strategy is 
conventionally used; escalating immunosuppression with cor-
ticosteroids, thiopurines, and then biological therapies only if a 
treatment-refractory course evolves. Recently, an alternative “top-
down” strategy has been advocated, following evidence that early 
use of anti–TNF-α therapies induced higher remission rates in 
CD (4). In support of this, subgroup analyses of anti–TNF-α tri-
als demonstrate higher response rates when these treatments are 
introduced earlier (5).
While trial evidence supports early aggressive therapy, safety 
concerns exist regarding the indiscriminate implementation of 
this strategy. These include the unnecessary immunosuppres-
sion of patients who were destined to experience an indolent 
course, even without additional therapies (2, 3), and the rare but 
potentially life-threatening side effects of such drugs, including 
opportunistic infection (6), demyelination (7), and malignancy 
(8). Moreover, use of biological therapy in all patients would be 
prohibitively expensive.
Accordingly, the ability to reliably predict an individual’s prog-
nosis, such that treatment strategies could be appropriately 
personalized from diagnosis, would represent a major clinical 
advance. Previous attempts to identify prognostic markers have 
focused on clinical parameters, but these factors (including 
younger age at diagnosis, early steroid requirement, and perianal 
involvement in CD) lack specificity, and hence are not clinically 
useful (9, 10). Biomarkers have also been studied, including anti–
Saccharomyces cerevisiae antibodies (ASCAs). ASCA seropositivity 
has been repeatedly associated with need for surgery in CD, but 
these reports are largely retrospective and confounded by the 
trend to increasing ASCA titers with time (11, 12). Likewise, genet-
ic variants at NOD2 (13) and HLA-DRB1*0103 (14) are statistically 
associated with need for surgery in CD and UC, respectively, but 
their poor sensitivity and the low frequency of the *0103 variant 
precludes their clinical use.
We recently observed that a common CD8 T cell transcriptional 
signature could be detected in 2 unrelated, autoimmune diseases — 
SLE and ANCA-associated vasculitis (AAV) — and that this pre-
dicted disease prognosis in both (15). UC and CD are not classi-
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cal autoimmune diseases, being thought to arise from an inap-
propriate immune response to gut microbiota, rather than to self 
antigens (16). However, irrespective of their classification, these 
diseases share a relapsing-remitting course driven by immunologi-
cal responses to antigen(s); prompting us to hypothesise that an 
equivalent transcriptional signature might exist in CD and/or UC 
and, if present, would correlate with prognosis. We also investi-
gated CD4 T cells for similar, clinically relevant transcriptional 
signatures, given that these are conventionally thought to be more 
important in IBD pathogenesis (17).
Results
We prospectively recruited 35 patients with active CD and 32 
patients with active UC, prior to commencing treatment. Of these 
patients, 58% were newly diagnosed (23 out of 35 patients with CD 
and 16 out of 32 patients with UC). At enrollment, CD4 and CD8 
T cells were positively selected from PBMCs for whole-genome 
transcriptional analyses. Patients were then managed convention-
ally using a step-up strategy by clinicians blinded to the microarray 
results (Supplemental Tables 1 and 2; supplemental material avail-
able online with this article; doi:10.1172/JCI59255DS1). We initially 
used an unsupervised approach to independently analyze the CD8 
T cell gene expression data from each disease cohort, after filtering 
out genes that were not expressed. In both diseases, the distribution 
of the data was significantly different from that of the multivariate 
Gaussian distribution that would be expected if no substructure was 
present (P < 1 × 10–15). To investigate this further, we used consensus 
clustering (18), which iteratively resamples and clusters fractions of 
the data and provides a consensus output indicating whether stable 
and reproducible clusters/subgroups are present. This is superior 
to standard clustering algorithms, as it enables evaluation of which 
(and how many) clusters are genuinely present, as opposed to being 
artefacts of sampling variation. This demonstrated that the reason 
why we were unable to model either of the CD8 T cell transcrip-
tional data sets with a Gaussian distribution was because 2 distinct 
patient subgroups were present within each disease cohort. Notably, 
these subgroups were detectable even if different clustering meth-
ods were used (k-means and hierarchical clustering) (Figure 1 and 
Supplemental Figure 1), although they could not be detected in 
unseparated PBMCs in either disease (Supplemental Figure 2).
Figure 1
Overlapping CD8 T cell gene expression signatures divide patients with CD and UC into 2 distinct subgroups. Consensus clustering heat maps, 
demonstrating the merged output of 5,000 iterations of hierarchical and k-means clustering of (A) patients with CD and (B) patients with UC. 
Patient samples are arranged in the same order along the x and y axes. The colors of the intersecting squares represent the frequency with 
which samples cluster together, both within individual consensus clustering analyses and also between analyses using different methods of 
clustering. The color ranges from red (patients always cluster together) to blue (patients never cluster together). (C) Venn diagram illustrating 
the overlap between the gene signatures that distinguish the respective subgroups in CD, UC, and SLE/AAV (15). The statistical significance 
of each overlap was determined using a hypergeometric test. Numbers in the diagram refer to numbers of genes. Those inside the circles refer 
to the genes that are within each respective signature. The number outside the circles refers to the remaining genes expressed in CD8 T cells, 
which were not differentially expressed in any of the signatures. (D) The clusters of CD patients that were produced by k-means clustering for 
this cohort using the gene signature generated in the UC patients and (E) vice versa. The colored bar beneath each dendrogram corresponds 
to the original IBD1/2 subgroup membership.
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Next, we derived the lists of genes (signatures) that were differen-
tially expressed between the 2 patient subgroups in each cohort. Of 
13,250 genes that were considered to be expressed, 3,403 genes in 
the CD cohort and 4,186 genes in the UC cohort were significantly 
differentially expressed between the patient subgroups after correc-
tion for multiple testing (P < 0.05) (data not shown; deposited in 
ArrayExpress, accession E-MTAB-331; http://www.ebi.ac.uk/array-
express/experiments/E-MTAB-331). The expression of selected 
Figure 2
CD patients in subgroups IBD1 and IBD2 have significantly different disease courses. (A) Kaplan-Meier survival curves demonstrating the 
proportion of CD patients who did not require a subsequent treatment escalation (immunomodulator or surgery) after enrollment, as stratified 
by IBD1/2 subgroup (left) and ASCA serology (middle) and clinical parameters associated with complicated disease (right). Clinical parameters 
included age of less than 40 years at diagnosis, initial requirement for steroids, and perianal involvement. High risk of complicated disease was 
defined as 2 or more of these parameters; low risk was defined as fewer than 2 of these parameters. Statistical significance was determined 
using a log-rank test (df). Number at risk refers to the number of uncensored patients at each time point who remained at risk of requiring a 
treatment escalation. (B) Disease courses of all CD patients (y axis). The color of dotted lines reflects subgroup designation. In cases in which 
multiple treatment escalations are indicated, this universally reflects ongoing disease activity rather than intolerance to the initial treatment. 
Statistical significance was determined using a Fisher’s exact test (2 df). (C) Bayes’ nomogram demonstrating the effect that stratifying the CD 
cohorts by the IBD1/2 signature would have had upon the predicted requirement for treatment escalation: prior probability of treatment esca-
lation, 48.6%; positive likelihood ratio, (sensitivity/[1-specificity]) 5.29 (95% CI, 1.35–21); negative likelihood ratio, ([1-sensitivity]/specificity) 
0.46 (95% CI, 0.26–0.84); post-test probabilities, IBD1, 83% (95% CI, 56%–95%), and IBD2, 30% (95% CI, 20%–44%).
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genes was validated by qPCR (Supplemental Figure 3). Comparison 
of these signatures revealed highly significant overlap (hypergeo-
metric P < 1 × 10–300; Figure 1). Indeed, this overlap was so con-
siderable that both signatures could be used interchangeably, each 
being able to exactly reproduce — in the other disease cohort — the 
same subgroups that had been detected in the unsupervised analy-
sis (Figure 1). Moreover, we were also able to generate smaller lists 
of genes, selected on their ability to distinguish the subgroups in 
half of the entire patient cohort, which could accurately designate 
patients with either CD or UC in the other independent half into 
their correct subgroups. The performance of these “classifiers” was 
similar, irrespective of the methods used to generate them or the 
number of genes they contained (between 4 and 100). An example 
is shown in Supplemental Figure 4 (positive predictive value 100%, 
negative predictive value 100%). We therefore termed the corre-
sponding patient subgroups defined by these analogous signatures 
as “IBD1” (the subgroup characterized by elevated expression of 
the majority of differentially expressed genes) and “IBD2” (the sub-
group characterized by lower expression of these genes).
Comparison with the SLE/AAV prognostic transcriptional signature. 
Given our original hypothesis, we then compared these tran-
scriptional signatures with the prognostic signature detected in 
AAV and SLE (15). The genes within the analogous UC and CD 
signatures highly overlapped with those within the SLE/AAV sig-
nature (hypergeometric P < 1 × 10–300; Figure 1), with reciprocal 
enrichment of the upregulated and downregulated SLE/AAV sig-
nature genes in the corresponding parts of the IBD1/2 signature 
(Supplemental Figure 5). Accordingly, these data confirm that the 
transcriptional signatures that we have independently detected in 
CD and UC are analogous to a prognostic signature previously 
detected in unrelated autoimmune diseases.
The IBD1/2 signature predicts subsequent disease course in UC and CD. 
We then investigated whether subgroups IBD1 and IBD2 cor-
related with clinical course in UC and CD. In both diseases, an 
early indicator of an aggressive/progressive course is that an 
individual’s disease is persistently active, either in a continu-
ous or a frequently relapsing fashion. The common end point 
for either of these patterns of disease behavior is the necessity 
to escalate treatment; initially with oral immunomodulators 
and subsequently — if disease activity persists — with alternative 
immunomodulators, biological therapies, or surgery. As patients 
with quiescent disease do not receive any such treatment escala-
tions, we used the requirement to introduce such therapies after 
initial induction of disease remission to assess disease course 
(Supplemental Tables 1 and 2). In the CD cohort, patients in 
subgroup IBD1 (characterized by upregulation of the majority of 
differentially expressed genes) experienced relapsing or chroni-
cally active disease, such that a treatment escalation was neces-
sary, significantly more frequently than those in subgroup IBD2 
(P = 0.003; Figure 2). Moreover, of all the patients who required a 
treatment escalation at any stage, those in subgroup IBD1 were 
significantly more likely to continue to experience persistently 
active disease, despite the initial intervention, necessitating one 
or more further treatment escalations (P = 0.01; Figure 2 and 
Supplemental Figure 6). Of note, all additional treatment escala-
tions were due to ongoing disease activity rather than intolerance 
to the initial treatment.
In the UC cohort, patients in subgroup IBD1 also experienced a 
more aggressive disease course than those in subgroup IBD2. This 
was similarly characterized by a higher incidence of recurrently 
active disease requiring immunomodulators (P = 0.0002; Figure 3). 
The total number of escalations required throughout the follow-
up period was also higher, as was observed in the CD IBD1 sub-
group (P = 0.002; Figure 3).
To provide a direct estimate of the prognostic utility of this 
signature, we calculated the specificity (CD, 89%; UC, 84%) and 
sensitivity (CD, 59%; UC, 77%) of its ability to predict the future 
requirement for any treatment escalation. Using these values, we 
derived positive and negative likelihood ratios for each disease, 
which were then applied to the overall prevalence of requiring a 
treatment escalation in our cohorts (CD, 48.6%; UC, 40.6%). This 
was performed using a Bayes nomogram (19), which is a graphi-
cal tool for estimating how much a test can alter the probability 
of a particular outcome — in this case that a treatment escalation 
would be required in the future due to continuously active or fre-
quently flaring disease. The results are shown in Figures 2 and 3  
and demonstrate that prestratifying patients with CD or UC 
according to their IBD1/2 subgroup membership would have 
effectively distinguished those patients who were destined to 
experience more aggressive disease from those who went on to 
experience indolent disease.
We then investigated whether we could identify these patient 
subgroups by other means. We observed no significant associa-
tion between the subgroups and any contemporaneous laboratory 
or clinical parameters recorded at enrollment (Table 1). There was 
also no association with prior duration of disease, the subgroups 
being detectable in both newly and previously diagnosed patients 
(Table 1). Accordingly, at enrollment, it was not possible to iden-
tify the subgroup to which a patient belonged by other means.
We then considered other clinical and serological parameters, 
which have been reported to associate with disease course based 
on analysis of retrospective data. In CD, the development of more 
aggressive disease has been associated with 2 or more of the follow-
ing factors: age of less than 40 years at diagnosis, early requirement 
for corticosteroids, and perianal disease (9). In UC, extensive dis-
ease and older age have been reported to be “negative prognostic 
predictors” (20). We therefore stratified both cohorts into high- 
and low-risk subgroups according to these clinical risk factors but 
did not detect any prognostic association with disease course in 
either cohort (Figures 2 and 3). We also assessed S. cerevisiae serol-
ogy in the CD cohort. Fifty-one percent of patients were ASCA 
positive at enrollment, which correlated significantly with previ-
ous diagnosis (P = 0.01, Fisher’s exact test) but not with subse-
quent disease course (P = 0.54; Figure 2).
Pathway analysis. Due to the large size of these signatures, we 
investigated whether the differentially expressed genes were coor-
dinately found within specific cellular pathways that could eluci-
date aspects of the underlying biology. This was performed using 
Gene-Set Enrichment Analysis (GSEA) (21), which is a computa-
tional method that determines whether the expression of whole 
lists of genes (predefined as being implicated in specific pathways) 
is significantly and concordantly different between 2 biological 
states (in this case IBD1 and IBD2). We did this instead of focusing 
on individual genes, as, while many are likely to have been of inter-
est, they are — in isolation — less likely to have had substantial bio-
logical effects (21). We observed significant, reproducible enrich-
ment for several pathways (Supplemental Table 3), including TCR 
signaling, CD28 costimulation, IL-7 signaling, and IL-2 signaling 
(Supplemental Table 4 and Supplemental Figure 7). These path-
ways, which are upregulated in IBD1 patients, are implicated in T 
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cell activation and the subsequent development of antigen-specific 
T cell memory (22, 23), implying that there may be a difference in 
the activation status of CD8 T cells between the subgroups. To 
further investigate this, we then examined whether a signature of 
CD8 T cell activation, which was derived experimentally by stimu-
lating primary human CD8 T cells (24), was enriched within the 
transcriptional signature that distinguished subgroups IBD1 and 
IBD2. Experimentally derived signatures have one advantage over 
annotated signatures, as they are not reliant upon data curation but 
rather reflect the sum of the transcriptional changes — through-
out the whole genome — that are induced upon activation. This 
demonstrated that there was a significant difference in CD8 T cell 
activation status between the IBD1 and IBD2 patients (P = 0.048; 
Supplemental Figure 8), with T cell activation genes being 
Figure 3
UC patients in subgroups IBD1 and IBD2 also have significantly different disease courses. (A) Kaplan-Meier survival curves demonstrating the 
proportion of UC patients who did not require a subsequent treatment escalation (immunomodulator or surgery) after enrollment as stratified by 
IBD1/2 subgroup (left), age at diagnosis (middle), and disease extent (right). Statistical significance was determined using a log-rank test (1 df). 
Number at risk refers to the number of uncensored patients at each time point who remained at risk of requiring a treatment escalation. (B) Disease 
courses of all UC patients (y axis). Format is identical to that used in Figure 2B. Statistical significance was determined using a Fisher’s exact test 
(2 df). (C) Bayes’ nomogram demonstrating the effect that stratifying the UC cohorts by the IBD1/2 signature would have had upon the predicted 
requirement for treatment escalation: prior probability of treatment escalation, 40.6%; positive likelihood ratio, 4.87 (95% CI, 1.65–14); negative 
likelihood ratio, 0.27 (95% CI, 0.10–0.75); post-test probabilities, IBD1, 77% (95% CI, 53%–91%), and IBD2, 16% (95% CI, 6%–34%).
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expressed at a relatively higher level in the IBD1 patients — consis-
tent with the implications of the pathway analysis results. Finally, 
we examined whether we could detect any differences in the rela-
tive size or surface phenotype of the cellular subsets of CD8 T cell 
memory (including central and effector memory populations; ref. 
25) by contemporaneous flow cytometry. Notably, when examin-
ing these memory subpopulations — which will have contained 
cells specific to a range of antigens (not just those specific to IBD-
related epitopes) — we were not able to detect any significant dif-
ferences between the subgroups (Supplemental Figure 9).
Transcriptional differences in CD4 T cells do not predict disease course. 
There is a large body of evidence implicating roles for various CD4 
T cell subsets in the pathogenesis of both CD and UC. We therefore 
used the same methodology to analyze the expression data from 
the 13,709 genes deemed to be expressed in CD4 T cells. Although 
we detected significant substructure in each disease cohort that 
was best described by the presence of 2 subgroups, these were less 
distinct than those observed in the CD8 T cell gene expression 
data (Supplemental Figure 10), and different clusters of patients 
were produced in both cohorts depending on the clustering algo-
rithm used. We compared the lists of genes that were differentially 
expressed between the CD4 subgroups in each disease but failed 
to demonstrate significant overlap (P = 0.12). Furthermore, these 
subgroups did not correlate with subsequent disease course (Sup-
plemental Figure 10) or any other clinical parameter.
Discussion
A major barrier to personalized medicine in IBD is the lack 
of suitable biomarkers to guide treatment early in the disease 
course. In oncology, gene expression profiling has been used to 
identify transcriptional signatures that predict several aspects 
of disease behavior, including risk of metastasis and response 
to chemotherapy (26–28). Where such techniques have previ-
ously been applied to autoimmune and inflammatory condi-
tions, they have generally not detected signatures with equiva-
lent prognostic utility. This may have been because the tissues 
commonly examined, such as PBMCs or mucosal biopsies, are 
heterogeneous, and hence any transcriptional variation detected 
will predominantly reflect differences in the cellular composi-
tion between samples. Indeed, such analyses have been shown 
to be insensitive to the differences that may have been detect-
able in separated cell subsets (29). Recently, using separated 
CD8 T cells, we have identified what we believe to be a novel 
transcriptional signature that predicted outcome in SLE and 
AAV and that was enriched for genes within the IL-7 and TCR 
signaling pathways. We therefore set out to investigate whether 
this transcriptional signature might exist in patients with CD 
and UC, which, despite being very different conditions, share a 
relapsing-remitting course driven by immunological responses 
to antigen(s). In both UC and CD, we identified, using an unsu-
pervised approach, a common transcriptional signature in sepa-
rated CD8 T cells that was analogous to the prognostic signa-
ture previously described in SLE and AAV. In both IBD cohorts, 
patients whose CD8 T cells were enriched for this signature 
(subgroup IBD1) had a substantially higher incidence of expe-
riencing treatment-refractory, relapsing, or chronically active 
disease — concordant with the clinical phenotype observed in 
SLE and AAV. These observations therefore validate our a priori 
hypothesis that the signature may be present and that, if pres-
ent, it would associate with altered prognosis.
Table 1
Baseline characteristics
	 	 CD	 	 	 UC	
	 IBD1	(n	=	12)	 IBD2	(n	=	23)	 P	 IBD1	(n	=	13)	 IBD2	(n	=	19)	 P
Age (yr)A 27.5 (25.9–32.6) 34.0 (27.7–44.1) 0.19 48.8 (36.3–50.8) 40.8 (29.3–49.5) 0.38
Hemoglobin (g/dl)A 13.2 (12.2–14.4) 12.5 (11.6–13.8) 0.51 14.0 (13.5–14.4) 13.1 (12.4–14.8) 0.51
AlbuminA 35.5 (32–38) 36 (34–39) 0.45 40 (38–41) 40 (39–41) 0.60
CRP (mg/l)A 24 (14–35) 23 (10–51) 0.93 7 (6–33) 10 (6–19) 0.80
ESR (mm/h)A 25 (16–35) 25 (18–41) 0.66 16 (11–27) 18 (11–26) 0.87
HBSIA 10.5 (8–12.5) 10 (9–12) 0.77 – – –
SCCAIA – – – 10 (8–11) 8 (7–9) 0.27
Follow-up (d)A 526 (476–647) 531 (428–659) 0.82 575 (435–685) 562 (475–643) 0.27
Previously diagnosedB 5 (42%) 7 (30%) 0.71 8 (62%) 8 (42%) 0.45
Sex (M)B 5 (42%) 9 (39%) 1.00 6 (46%) 6 (32%) 0.47
SmokerB 5 (42%) 11 (48%) 1.00 1 (8%) 0 (0%) 0.41
ASCA seropositiveB 5 (42%) 13 (57%) 0.49 – – –
Disease distributionB,C      
CD – L1 (ileal) 2 (17%) 5 (22%) 1.00 – – –
CD – L2 (colonic) 4 (33%) 5 (22%) 0.69 – – –
CD – L3 (ileocolonic) 6 (50%) 13 (57%) 0.74 – – –
CD – L4 (upper GI) 0 (0%) 2 (9%) 0.54 – – –
Perianal 2 (17%) 2 (9%) 0.59 – – –
UC – E1 (proctitis) – – – 3 (23%) 3 (16%) 0.67
UC – E2 (left-sided) – – – 4 (31%) 9 (47%) 0.47
UC – E3 (extensive) – – – 6 (46%) 7 (37%) 0.72
Data shown in parentheses indicate median (interquartile range) values or percentages unless specified. AStatistical significance was calculated using a Mann-
Whitney test (2 tailed) for continuous variables and Ba Fisher’s exact test (2 tailed) for dichotomous variables. CDisease distribution was classified according to 
the Montreal Classification (29). GI, gastrointestinal; HBSI, Harvey-Bradshaw severity index; M, male; SCCAI, simple clinical colitis activity index.
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The patterns of relapsing or chronically active intestinal inflam-
mation that were commonly experienced by patients in the IBD1 
subgroup are associated with considerable morbidity, including 
the development of medically irreversible complications, and 
represent the courses of disease most likely to benefit from early 
top-down therapy (5). Accordingly, these data suggest that gene 
expression profiling may represent the first method by which treat-
ment strategies could be appropriately personalized at diagnosis. 
Such preemptive stratification would be expected to improve the 
therapeutic outcome in those patients with IBD destined to run a 
refractory course and avoid unnecessary immunosuppression in 
those with indolent disease. However, as a top-down strategy was 
not used in our cohorts, these expected results require confirma-
tion in a prospective trial.
It is not possible to fully elucidate the biological differences 
that account for such transcriptional variation with this sort 
of microarray-based study. However, it is noteworthy that path-
way analysis identified several pathways — upregulated in IBD1 
patients — that are associated with the activation of CD8 T cells 
in response to MHC class I–bound antigen and their subsequent 
proliferation and differentiation into effector cells (TCR signal-
ing, CD28 costimulation, and IL-2 signaling). This would imply 
that concordant differences in the activation status of CD8 T 
cells may contribute to the differences between these subgroups. 
Consistent with this, we observed that CD8 T cells from IBD1 
patients were relatively enriched for a CD8 T cell activation sig-
nature in comparison with those from IBD2 patients. Studies of 
how memory T cells are generated after antigen exposure have 
shown that the more activated T cells become in response to an 
antigen (reflected in the “clonal burst” size), the more memory T 
cells are subsequently formed (30). Notably, the other key deter-
minant of memory T cell generation is IL-7 signaling, which 
facilitates the survival and differentiation of effector cells into 
long-lived antigen-specific memory cells (23) and which was also 
upregulated in IBD1 patients. Accordingly, the combination of 
greater T cell activation in conjunction with greater IL-7 signal-
ing would be expected to result in more antigen-specific memory 
being generated in IBD1 patients, which would, in turn, facili-
tate more rapid and potent CD8 effector responses upon future 
reencounters with that antigen (31). Such antigen-specific, cyto-
toxic CD8 T cells are known to be detectable in increased num-
bers in the intestinal mucosa in active CD and UC (32, 33), and 
therefore it would seem plausible that differences in antigen-
specific T cell memory between the subgroups could manifest 
clinically as differences in the future behavior of these relapsing-
remitting immune-driven diseases. However, while these data are 
consistent with a role for CD8 T cells in determining the natural 
history of both UC and CD, they do not prove that this is the 
case. Indeed, confirmation of whether correlation exists between 
the quality or quantity of antigen-specific memory formed dur-
ing a flare and subsequent disease course will probably require 
knowledge of the specific antigens involved, as no differences 
were detectable in the overall CD8 T cell memory compartments 
(as assigned by expression of surface markers). Importantly, this 
result was not unexpected, and it does not disprove that dif-
ferences in memory T cells may exist between the subgroups. 
This is because the memory compartments examined by flow 
cytometry will have contained cells specific to a variety of pre-
viously encountered antigens — not just those associated with 
IBD. This heterogeneity would obviously limit our ability to 
detect differences that only involve a subpopulation of memory 
cells (e.g., those specific to IBD-associated antigens). However, 
these differences could still be detectable at a gene expression 
level, due to the increased transcriptional activity of this sub-
population of cells during an antigen-specific immune response 
(i.e., a disease flare). A further potentially confounding issue is 
that the assignment of “memory” function on the basis of the 
expression of a few surface markers is known to be imperfect 
(34). Accordingly, any discrepancy between immunophenotype 
and function would also reduce our ability to detect potential 
differences between the subgroups.
Another question, which these data present, but which also can-
not be directly addressed in such a microarray-based study, is the 
mechanism(s) that underlies such transcriptional variation, as 
this could reveal novel therapeutic targets. One possibility would 
be that the differences arise as a primary phenomenon (e.g., due to 
differences in genetic, ref. 35, or epigenetic variation, ref. 36–38), 
such that CD8 T cells from the 2 subgroups were predestined to 
respond differently to antigen. This could still feasibly be consis-
tent with differences in IL-7 signaling between the IBD1 and IBD2 
subgroups, as this pathway is also critical in T cell development 
through supporting the differentiation of common lymphoid pre-
cursors (39). However, if this were true, one might have expected 
the resulting differences in the number of effector and memory 
cells to be detectable by flow cytometry, given that all antigen 
responses would be expected to be similarly affected. Alternative-
ly, these differences could arise as a secondary effect and hence 
be contingent upon the context in which CD8 T cells encoun-
ter antigen. This would implicate other cells in driving the tran-
scriptional differences, such as antigen-presenting cells and/or 
helper CD4 T cells (22).
The lack of clinically relevant transcriptional variation in CD4 
T cells is noteworthy in the context of the CD8 T cell prognostic 
signature, particularly as CD4 T cells are traditionally thought 
to be more important in IBD pathogenesis. While this result 
may therefore appear surprising, there are several reasons why 
these data do not conflict with current models of disease patho-
genesis. First, although a prognostic signature was not present 
in CD4 T cells, this does not imply that they are not involved in 
affecting disease prognosis, only that their involvement is of a 
nature that cannot be wholly reflected in simple transcriptional 
changes. Indeed, it is even possible that the CD8 T cell transcrip-
tional signature is a secondary phenomenon arising from other 
immunological events associated with disease pathogenesis. 
These could include CD4 T cell responses, which are known to 
be required for the development of effective CD8 T cell memory 
(22). Second, although there is no reason to suppose that a prog-
nostic CD4 T cell signature must exist, the relative heterogeneity 
of circulating CD4 T cells (which comprise varying proportions 
of Th subsets [including Th1, Th2, and Th17] and regulatory 
T cells) will have reduced our sensitivity to detect such a sig-
nature (29). It could therefore be speculated that an equivalent 
prognostic signature might exist in one of the CD4 Th subsets, 
although in order to test this hypothesis, it would have been nec-
essary to contemporaneously isolate and array these individual 
subpopulations. Third, while the full complexity of the adaptive 
immune response in IBD is not well understood, it is clear that 
CD8 T cells — as well as CD4 T cells — do have an important 
role. Indeed, in addition to activated effector CD8 T cells being 
detectable in the mucosa in IBD, several animal models (40–43) 
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have suggested it is the destruction of intestinal epithelial cells 
by CD8 T cells that represents the primary event leading to the 
loss of barrier function and enhanced exposure to microbial 
antigens that ultimately drives disease activity. Accordingly, it 
has been proposed that CD8 T cells may play an earlier role in 
IBD development or relapse than the CD4 T cells that are more 
traditionally associated with disease pathogenesis (44), which 
may be relevant in the context of our observations.
It is interesting that our data confirm both the existence of this 
signature and its association with more aggressive disease behav-
ior in 2 diseases that, although being immunologically driven, are 
not traditionally classified as being autoimmune. Genetic stud-
ies have previously shown that certain polymorphisms can con-
tribute to the development of several different diseases (45). Our 
data suggest that as well as sharing common genomic variation, 
distinct disease states can also be influenced by common varia-
tion at the level of the transcriptome and that this can have direct 
relevance for disease prognosis. The common underlying biology 
accounting for this could include, for example, features of the 
CD8 T cell response to MHC class I–restricted antigen, which 
would be consistent with the pathway analysis results and the 
differences observed in subsequent disease course. Interestingly, 
this would mean that such transcriptional differences can occur 
— and can be detected — irrespective of the nature of the caus-
ative antigen(s) (self vs. foreign) or the genetic and environmen-
tal susceptibility factors that combine with the immune response 
to determine the resulting disease phenotype. While this is only 
one possible explanation, it is not necessary to understand the 
precise mechanism(s) to appreciate that there are wide-ranging 
implications of the observation that generic, rather than disease-
specific, factors may significantly affect the natural history of 
distinct immune-driven diseases. Indeed, we would ultimately 
hope that better characterization of the biology that underlies 
this transcriptional variation might reveal novel therapeutic tar-
gets that could be relevant for several diseases in which effector 
T cells play a role in pathogenesis.
In conclusion, we have shown that a gene expression signature, 
detectable at diagnosis in patients with UC and CD, is associated 
with a significantly more aggressive disease course in both condi-
tions. This represents, to our knowledge, the first biomarker that 
has been prospectively shown to predict the course of both UC 
and CD from diagnosis. This could therefore enable patients with 
either condition to be stratified to receive personalized therapy 
according to their disease prognosis and, accordingly, represents 
a major step toward individualized management in the treatment 
of these common and disabling conditions.
Methods
Patient recruitment. Patients with active CD and UC were recruited from a 
specialist IBD clinic at a tertiary referral hospital, prior to commencing treat-
ment. Diagnosis was made using standard endoscopic, histologic, and radio-
logical criteria (46). Patients receiving immunomodulators or corticosteroids 
were excluded due to potential effects on gene expression. Enrolled patients 
were managed conventionally using a step-up strategy (Supplemental Tables 
1 and 2). Assessment of disease activity was in accordance with national and 
international guidelines and included consideration of symptoms, clini-
cal signs, and objective measures, including blood tests (C-reactive protein 
[CRP], erythrocyte sedimentation rate [ESR], hemoglobin concentration, 
and serum albumin), stool markers (calprotectin), and mucosal assessment 
(by sigmoidoscopy or colonoscopy) where appropriate. Validated scoring 
tools were used as another means of assessing disease activity (Harvey-Brad-
shaw severity index, ref. 47, or simple clinical colitis activity index, ref. 48, for 
CD and UC, respectively), although these were not used to guide treatment 
decisions. All clinicians were blinded to the microarray results.
Cell separation. A 110-ml blood sample was taken from eligible patients. 
A 10-ml sample was used for flow cytometric immunophenotyping and to 
obtain serum. PBMCs were isolated by density centrifugation, and CD4 
and CD8 T cells were positively selected as previously described (49) (medi-
an purity, 93.8% and 91.0%, respectively).
RNA extraction and microarray analysis. RNA was extracted from PBMC and 
CD4 and CD8 T cell lysates using RNEasy Mini Kits (Qiagen) according to 
the manufacturer’s instructions. RNA quantity and quality were determined 
using a NanoDrop 1000 Spectrophotometer (Thermo Scientific) and an 
Agilent 2100 Bioanalyzer (Agilent Technologies). 200 ng RNA was processed 
for hybridization onto Affymetrix Human Gene ST 1.0/1.1 microarrays, 
according to the manufacturer’s instructions, prior to scanning.
Data analysis. Raw data were preprocessed (normalization [vsnrma], refs. 
50, 51; quality-control evaluation, ref. 52; and batch effect correction, ref. 
53) using BioConductor (http://www.bioconductor.org/) in R (http://
www.r-project.org/). A gene filter was used to exclude genes that were not 
expressed but which could affect any results through noise. This excluded 
probes whose signal intensity value was below a background level (set using 
a reference control data set) in more than 10% of samples. To test our a priori 
hypothesis that a clinically relevant transcriptional signature would exist, 
we first used unsupervised consensus clustering (5,000 iterations, 80% sub-
sampling) to investigate whether any subgroups were present in either the 
CD4 or CD8 T cell gene expression data from both diseases (18). This was 
performed using k-means and hierarchical clustering to enable comparison 
of the results between clustering algorithms (54). The significance of any 
apparent substructure was determined by comparing the distribution of our 
data with that which would be expected if no substructure was present (55).
Differentially expressed genes were identified using linear modeling and 
an empirical Bayes method (56). We used a family-wise error rate method 
to correct for multiple testing. This particularly stringent correction was 
chosen over more liberal methods, because avoidance of type-1 errors was 
more important than optimization of statistical power (at the expense of 
including false positives). GSEA (21) was used to assess whether the differ-
entially expressed genes were enriched within specific biological pathways. 
We initially used the database of pathways that have been curated from 
BioCarta (http://www.biocarta.com) by the Molecular Signatures Data-
base (http://www.broadinstitute.org/gsea/msigdb) (21) and subsequently 
sought to confirm the implications of this analysis by using an experimen-
tally derived signature of CD8 T cell activation (24). The initial explor-
atory analysis was performed using independent subsets of the overall 
data set to confirm that any enrichment was reproducible. Pathways were 
considered significantly enriched if the enrichment (P < 0.05) was repro-
duced in the second independent cohort (P < 0.05; false discovery rate 
q < 0.25). We also used these cohorts to generate and test simpler methods 
of ascribing subgroup designation (using smaller numbers of genes than 
are assayed on a whole microarray) to ascertain whether a more practical 
test could be developed. Several methods of generating such classifiers 
were investigated, including weighted voting and random forests. Further 
details of the bioinformatic analyses are provided in the Supplemental 
Methods. Raw data, transformed data, and the transcriptional signatures 
are deposited in ArrayExpress (accession E-MTAB-331; http://www.ebi.
ac.uk/arrayexpress/experiments/E-MTAB-331).
Quantitative PCR. CD44, IL10RB, ILF2, and IL2RG mRNA levels were deter-
mined using TaqMan Expression Assays (Applied Biosystems) on an ABI 
Prism 7900HT instrument according to the manufacturer’s instructions. 
Transcript abundance was calculated by comparison with a standard curve.
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Immunophenotyping. Flow cytometric immunophenotyping of T cell memory 
compartments was performed on a CyAn ADP flow cytometer (Beckman Coul-
ter) using the following antibodies: CD3-PE/Cy5, CD8-Pacific Blue, CD45RA-
PE/Cy7, CD62L-FITC, CD127-PE, CD25-PE, and IgG1-PE isotype control 
(BD Biosciences). Data were analyzed using FlowJo software (TreeStar).
ELISAs. Sera were tested for the presence of S. cerevisiae IgA and IgG 
antibodies using a commercially available sandwich ELISA (ASCA Screen 
ELISA, IBL Hamburg) according to the manufacturer’s instructions.
Statistics. The statistical/bioinformatic analyses of microarray data are 
described in the Data Analysis section, with additional details in the Supple-
mental Methods. Other statistical analyses were as follows. The statistical 
significance of the overlap among any gene signatures was determined with 
a hypergeometric test (1 degree of freedom [1 df]). Comparison of the clinical 
and laboratory parameters among patients in different subgroups was per-
formed using Fisher’s exact test (1 df) for dichotomous variables and Mann-
Whitney test (2 tailed) for continuous variables. Comparison of the initial 
requirement for a treatment escalation was performed using a log-rank test 
(1 df) and graphically represented with a Kaplan-Meier plot. Comparison of 
the total number of treatment escalations required was performed using a 
Fisher’s exact test (2 df). The α value for these analyses was 0.05 and was cor-
rected for multiple testing (as detailed) where appropriate.
Study approval. Ethical approval was for this work was obtained from the 
Cambridgeshire Regional Ethics Committee (REC08/H0306/21). All par-
ticipants provided written informed consent.
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